FDA reviewing sBLA for Pegintron for melanoma
Schering-Plough Corporation has announced that FDA has granted priority review to its supplemental Biologics License Application for Pegintron (pegylated interferon alfa-2b) as adjuvant therapy for patients with stage III melanoma.
KENILWORTH, New JerseySchering-Plough Corporation has announced that FDA has granted priority review to its supplemental Biologics License Application for Pegintron (pegylated interferon alfa-2b) as adjuvant therapy for patients with stage III melanoma. The agent is currently approved for use in the treatment of chronic hepatitis C. The company said that FDA's Oncology Drugs Advisory Committee will discuss the application at its meeting in March.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
![A third of patients had a response [to lifileucel], and of the patients who have a response, half of them were alive at the 4-year follow-up.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F6b7c9a3270c71a70749ba86000cfc78a29d74309-2988x1702.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "A third of patients had a response [to lifileucel], and of the patients who have a response, half of them were alive at the 4-year follow-up.")
